The UWPKDAP (University of Washington Program on Pharmacokinetics of Drugs of Abuse during Pregnancy) is an NIH (NIDA)-funded research program in the Department of Pharmaceutics, School of Pharmacy at the University of Washington.
The primary purpose of the program is to elucidate the fundamental mechanisms of maternal-fetal drug disposition in pregnant women with special emphasis on drugs of abuse, treatment of drug abuse.
These data will be synthesized into Physiologically Based Pharmacokinetic (PBPK) models that will help predict maternal and fetal exposure to illicit and licit drugs used by pregnant women. The program, led by Dr. Jashvant Unadkat, consists of three projects.
(Co-PIs: Drs. Qingcheng Mao and Jashvant Unadkat; Co-investigators: Drs. Rodney Ho, Ed Kelly, Michael Gravett):
This project will systematically investigate gestational-age dependent changes (and their mechanistic basis) in hepatic CYP3A metabolism and placental transport (P-gp and BCRP) of drugs used to treat drug abuse (e.g. buprenorphine, norbuprenorphine and methadone).
(Co-PIs: Drs. Joanne Wang and Nina Isoherranen):
This project will characterize the gestational age-dependent changes in maternal and fetal exposure to amphetamines and elucidate the mechanisms underlying these changes.
(Co-PIs: Drs. Nina Isoherranen and Jashvant Unadkat; Co-investigators: Drs. Gail Anderson, Alyssa Stephensson-Famy and Justine Chung):
This project will study the disposition of bupropion (as a phenotypic marker of CYP2B6) in pregnant women as well as develop and validate PBPK models to predict maternal-fetal disposition of drugs of abuse (e.g. amphetamines) and drugs used to treat abuse (e.g. buprenorphine, methadone and bupropion).